Literature DB >> 7692605

Recurrent breast cancer: presentation, diagnosis, and treatment.

L Jardines1, L S Callans, M H Torosian.   

Abstract

Patients must be followed up closely after primary therapy for invasive breast cancer so that locoregional recurrences can be detected early. Once a recurrence has been detected, a thorough evaluation is indicated to exclude distant metastatic disease. If none is found, the patient may be a candidate for aggressive surgical intervention to render the patient disease-free. If distant disease is found, certain sites, such as the CNS or long bones, may warrant aggressive therapy because failure to treat these sites may lead to excessive morbidity. In most situations, patients with distant disease are treated with palliative measures. In selected instances, however, patients with metastatic breast cancer are candidates for aggressive intervention, including pulmonary or liver resection or high-dose chemotherapy in combination with autologous bone marrow transplantation, to rid the patient of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692605

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  15 in total

Review 1.  [Multimodality treatment concepts for metastatic breast cancer].

Authors:  V Heinemann; S Kahlert; H-J Stemmler
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

Review 2.  A role for hepatic surgery in patients with liver metastatic breast cancer: review of literature.

Authors:  Nicolae Bacalbaşa; Sorin Tiberiu Alexandrescu; Irinel Popescu
Journal:  Hepat Oncol       Date:  2015-05-15

3.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells.

Authors:  Qiang Shen; Eugene S Lee; Robert L Pitts; Mack H Wu; Sarah Y Yuan
Journal:  Mol Cancer Res       Date:  2010-06-22       Impact factor: 5.852

5.  Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres.

Authors:  Tobias F Jakobs; Ralf-T Hoffmann; Gabriele Poepperl; Anna Schmitz; Jürgen Lutz; Walter Koch; Klaus Tatsch; Andreas Lubiensky; Maximilian F Reiser; Thomas Helmberger
Journal:  Eur Radiol       Date:  2006-12-06       Impact factor: 5.315

6.  Radiofrequency ablation as a treatment strategy for liver metastases from breast cancer.

Authors:  Anne M Covey; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2008-12       Impact factor: 1.513

Review 7.  Radiotherapeutic approaches to metastatic disease.

Authors:  Edward Chow; Jackson Wu; Andrew Loblaw; Carlos A Perez
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

8.  Aggressive treatment for hepatic metastases from breast cancer: results from a single center.

Authors:  F Polistina; G Costantin; A Febbraro; E Robusto; G Ambrosino
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

Review 9.  [Therapy response of liver tumors after selective internal radiation therapy].

Authors:  T F Jakobs; R T Hoffmann; K Tatsch; C Trumm; M F Reiser
Journal:  Radiologe       Date:  2008-09       Impact factor: 0.635

10.  A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier.

Authors:  Hamed Kargozaran; Sarah Y Yuan; Jerome W Breslin; Katherine D Watson; Nathalie Gaudreault; Alison Breen; Mack H Wu
Journal:  Clin Exp Metastasis       Date:  2007-07-25       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.